Skip to main content
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. — Investor Relations & Filings

Ticker · SCNI ISIN · US09073Q3039 US Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2025-03-11 Regulatory Filings
Country US United States of America
Listing US SCNI

About Scinai Immunotherapeutics Ltd.

https://www.scinai.com/

Scinai Immunotherapeutics Ltd. is a clinical-stage biopharmaceutical company operating through two complementary business units. Its internal research and development division focuses on developing innovative biological products for inflammation and immunology (I&I), targeting autoimmune and infectious diseases. The core of its therapeutic pipeline is a platform of Alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies), developed for conditions such as psoriasis and asthma. The company's second unit, Scinai Bioservices, is a Contract Development and Manufacturing Organization (CDMO). It provides end-to-end services to biotech companies, supporting drug development from early research and process development through to cGMP-compliant manufacturing for clinical trials up to Phase 3.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form F-1. It is a correspondence related to a regulatory filing process rather than a financial report or announcement of financial results. The document is short (1310 characters) and does not contain financial data or detailed report content. It is primarily a regulatory communication regarding the registration statement's effective date. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and correspondence.
2025-03-11 English
AMENDMENT NO. 1 TO FORM F-1
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus describing the offering of American Depositary Shares (ADSs) by a selling shareholder, details about the offering, risk factors, use of proceeds, capitalization, business description, management discussion and analysis, and other related information. The document is not an annual report, earnings release, or any other financial report but rather a registration statement and prospectus related to capital raising and securities offering. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2025-03-11 English
Regulatory Filings 2025
Regulatory Filings
2025-03-11 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains an explanatory note about a press release announcing a $10 million Standby Equity Purchase Agreement. The document itself is short (1974 characters) and primarily serves to furnish a press release as Exhibit 99.1. There are no detailed financial statements or substantive financial data included. The content is an update on financing activity but presented as a regulatory filing rather than a detailed capital/financing report. According to the rules, short documents that provide announcements or press releases without detailed financial data should be classified as Regulatory Filings (RNS).
2025-03-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-03-05 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933, used by companies planning an initial public offering (IPO) or other securities offering. The text includes a preliminary prospectus, details about the offering, selling shareholders, use of proceeds, risk factors, and other typical sections of a registration statement. It is not an annual report, earnings release, or any other type of financial report. It is a capital markets filing related to the registration and offering of securities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2025-03-04 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.